Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Youjin Oh

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-AnalysisWoojung Yang, Youjin Oh
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2026
CLO26-107: A Meta-Analysis and Network Meta-Analysis for Overall Survival of Pembrolizumab Monotherapy Versus Combined With Chemotherapy as First-Line Therapy in No EGFR/ALK-Mutation Advanced or Metastatic Non-Small-Cell Lung CancerWoojung Yang, Youjin Oh
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-107: A Meta-Analysis and Network Meta-Analysis for Overall Survival of Pembrolizumab Monotherapy Versus Combined With Chemotherapy as First-Line Therapy in No EGFR/ALK-Mutation Advanced or Metastatic Non-Small-Cell Lung CancerWoojung Yang, Youjin Oh
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2026
CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-AnalysisWoojung Yang, Youjin Oh
American Journal of Medical Genetics. Part A|March 21, 2023
De novo triplication at 1p36.23p36.22 further refines the dosage sensitive region of overlap in Setleis syndrome (focal facial dermal dysplasia type III)Rachel Youjin Oh, Kathy Chun, Paul E Kowalski, et al.
Molecules and Cells|October 7, 2024
Cellular and metabolic function of GIRK1 potassium channels expressed by arcuate POMC and NPY/AgRP neuronsYeeun Choi, Eun-Seon Yoo, Youjin Oh, et al.
JTO Clinical and Research Reports|September 30, 2024
Differentiation Syndrome in a Patient With NSCLC Harboring <i>IDH2</i> Mutation Treated With Enasidenib: Case ReportBhoomika Sukhadia, Dean Tan, Youjin Oh, et al.
Scientific Reports|December 9, 2020
Postoperative nutritional outcomes and quality of life-related complications of proximal versus total gastrectomy for upper-third early gastric cancer: a meta-analysisInhyeok Lee, Youjin Oh, Shin- Hoo Park, et al.
Cell Reports|November 2, 2022
Melanocortin-4 receptors activate sympathetic preganglionic neurons and elevate blood pressure via TRPV1Sang Hyeon Ju, Hyeonju Yun, Youjin Oh, et al.
Translational Lung Cancer Research|June 15, 2026
3D computed tomography airway geometry for predicting bronchoscopic accessibility in peripheral pulmonary nodules: a prospective studyByeong-Ho Jeong, Jonghoon Kim, Hwanho Cho, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-AnalysisWoojung Yang, Youjin Oh
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2026
CLO26-107: A Meta-Analysis and Network Meta-Analysis for Overall Survival of Pembrolizumab Monotherapy Versus Combined With Chemotherapy as First-Line Therapy in No EGFR/ALK-Mutation Advanced or Metastatic Non-Small-Cell Lung CancerWoojung Yang, Youjin Oh
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-107: A Meta-Analysis and Network Meta-Analysis for Overall Survival of Pembrolizumab Monotherapy Versus Combined With Chemotherapy as First-Line Therapy in No EGFR/ALK-Mutation Advanced or Metastatic Non-Small-Cell Lung CancerWoojung Yang, Youjin Oh
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2026
CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-AnalysisWoojung Yang, Youjin Oh
American Journal of Medical Genetics. Part A|March 21, 2023
De novo triplication at 1p36.23p36.22 further refines the dosage sensitive region of overlap in Setleis syndrome (focal facial dermal dysplasia type III)Rachel Youjin Oh, Kathy Chun, Paul E Kowalski, et al.
Molecules and Cells|October 7, 2024
Cellular and metabolic function of GIRK1 potassium channels expressed by arcuate POMC and NPY/AgRP neuronsYeeun Choi, Eun-Seon Yoo, Youjin Oh, et al.
JTO Clinical and Research Reports|September 30, 2024
Differentiation Syndrome in a Patient With NSCLC Harboring <i>IDH2</i> Mutation Treated With Enasidenib: Case ReportBhoomika Sukhadia, Dean Tan, Youjin Oh, et al.
Scientific Reports|December 9, 2020
Postoperative nutritional outcomes and quality of life-related complications of proximal versus total gastrectomy for upper-third early gastric cancer: a meta-analysisInhyeok Lee, Youjin Oh, Shin- Hoo Park, et al.
Cell Reports|November 2, 2022
Melanocortin-4 receptors activate sympathetic preganglionic neurons and elevate blood pressure via TRPV1Sang Hyeon Ju, Hyeonju Yun, Youjin Oh, et al.
Translational Lung Cancer Research|June 15, 2026
3D computed tomography airway geometry for predicting bronchoscopic accessibility in peripheral pulmonary nodules: a prospective studyByeong-Ho Jeong, Jonghoon Kim, Hwanho Cho, et al.
Pageof 4